The EIC Transition beneficiary Annaida Technologies, the first company to scale magnetic resonance technology down to the cellular level, has successfully closed an oversubscribed Pre-Series A funding round, led by HEMEX. This new capital will support the company’s product launch in the fertility market and drive continued innovation.
Annaida Technologies: a new way for cell metabolic analysis
A spin-off from EPFL (École Polytechnique Fédérale de Lausanne), Annaida Technologies is leading the ongoing EIC Transition project HYPERCELL, focusing on merging two groundbreaking technologies to validate a benchtop tool for cell metabolic analysis. The project promises to revolutionise cell research, and it aims to empower researchers to explore individual cell metabolic profiles, unveiling hidden disease mechanisms, understanding organism development, and revealing treatment responses. In addition, Annaida Technologies is pioneering micro magnetic resonance spectroscopy (micro-MRS) — a technology that enables non-invasive chemical analysis at microscopic scales.
For the first time, ANNAIDA’s technology can take MRS down to the microscale, allowing researchers to analyze samples from 50 microns to 1 millimeter in size. Its flagship device, Embryospin, harnesses this micro-MRS technology to identify and measure compounds in microscopic life forms. Already in use at leading academic institutions for cutting-edge magnetic resonance research, the platform has begun generating initial revenues from research-focused products. Looking ahead, Annaida envisions expanding its applications across the broader life sciences sector.
The pre-series A funding
In April 2025, Annaida announced the closure of an oversubscribed Pre-Series A funding round, led by HEMEX, which saw the participation from existing investors including Zürcher Kantonalbank (ZKB), Excellis, EFI Lake Geneva Ventures, and members of Club degli Investitori through Simon Fiduciaria. The capital raised, combined with the support from EIC Transition and Innosuisse (Swiss Innovation Project), placed Annaida in a strong position to mature its groundbreaking micro magnetic resonance platform into a commercial product.
Marco Grisi, Founder & CEO of Annaida, said:
These resources will help us grow our R&D activities and collaborations and establish market presence, pushing us closer to our vision of turning micro magnetic resonance into a tool that expands the boundaries of science (...). Specifically, by applying it to pre-implantation embryo analysis, we aim to help reduce the number of miscarriages in assisted fertility and offer a brighter future to millions of families.
Moreover, Pascal Winnen, HEMEX representative and member of Annaida’s Board of Directors, commented:
We’ve proudly supported Annaida Technologies since its inception in 2019 (...). As an early-stage investor, we are highly impressed by the company’s progress, the wide-ranging potential of its technology, particularly in the field of human fertility, and, above all, the team’s consistent ability to meet ambitious milestones and create substantial value for shareholders.
About Annaida Technologies
Born as a spin-off from EPFL, Annaida Technologies is now one of Europe’s most promising deep tech startups, pioneering micro magnetic resonance spectroscopy (micro-MRS) to enable non-invasive chemical analysis at microscopic scales. With initial applications in fertility and life sciences, Annaida is on a mission to transform micro-MRS into a platform for discovery, shifting the paradigm in how we assess and understand living systems at their earliest and most challenging stages.
Find out more about the EIC Transition HYPERCELL Project, visiting the Horizon Europe database and the company official website.
This article is based on the official press release issued on 29 April 2025, by Annaida Technologies.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.